Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of the Combination of the VEGFR Inhibitor, AZD2171, and MEK Inhibitor, AZD6244, in the Treatment of Solid Malignancies

Next Previous
Trial Profile

Phase I Study of the Combination of the VEGFR Inhibitor, AZD2171, and MEK Inhibitor, AZD6244, in the Treatment of Solid Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cediranib (Primary) ; Selumetinib (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Carcinoma; Colorectal cancer; Liver cancer; Malignant melanoma; Neuroendocrine carcinoma; Osteosarcoma; Ovarian cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer; Urogenital cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 08 Mar 2024 Planned End Date changed from 1 Jun 2016 to 7 Mar 2025.
    • 08 Mar 2024 Planned End Date changed from 1 Jun 2016 to 7 Mar 2025.
    • 13 Sep 2021 Results assessing the maximally tolerated dose of cediranib and selumetinib in combination, toxicity profile, and assess for disease activity published in the Investigational New Drugs
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top